Abstract: Provided are compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain compositions comprise a. about 0.1 wt. % to about 7.5 wt. % glycolic acid; b. about 0.1 wt. % to about 5 wt. % gluconolactone; c. about 0.1 wt. % to about 5 wt. % mandelic acid d. a glycol; e. a salt-tolerant thickening polymer, wherein the total amount of glycolic acid, gluconolactone and mandelic acid is less than about 15 wt. % of the total composition.

Abstract: Apparatus, system and method for a predictive risk manager for managing a supply chain comprising a plurality of supply chain nodes. Included in a risk manager are: a managing central hub comprising a plurality of primary data regarding anonymized hardware and software product data from the plurality of supply chain nodes, and life cycle data for all parts employed at the plurality of supply chain nodes; an input to the managing central hub comprising current proprietary data regarding a product made at one of the plurality of supply chain nodes; a plurality of rules capable of recognizing a predictive non-competitive part related risk embedded in the proprietary data, the plurality of rules calculating a recommended redesign to address the predictive non-competitive part related risk before it arises; and an output from the managing central hub to a graphical user interface, wherein the non-competitive part related risk and the recommended redesign are presented on the graphical user interface.

Abstract: A mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprises one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The one or more mutation is preferably within the extracellular leucine-rich repeat domain (LRD) of the TSHR, or within residues 22 to 260 (TSHR260) of the TSHR, or may be in the transmembrane domain (TMD), A mutant TSHR or fragment thereof of the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. A mutant TSHR or fragment thereof according to the invention has a greater thermostability than the equivalent wild type TSHR or fragment as determined by its half-life at a given temperature, and can be purified whilst retaining activity. A mutant TSHR or fragment thereof according to the invention may also be deglycosylated whilst retaining activity.

Abstract: A mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprises one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The one or more mutation is preferably within the extracellular leucine-rich repeat domain (LRD) of the TSHR, or within residues 22 to 260 (TSHR260) of the TSHR, or may be in the transmembrane domain (TMD), A mutant TSHR or fragment thereof of the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. A mutant TSHR or fragment thereof according to the invention has a greater thermostability than the equivalent wild type TSHR or fragment as determined by its half-life at a given temperature, and can be purified whilst retaining activity. A mutant TSHR or fragment thereof according to the invention may also be deglycosylated whilst retaining activity.

Abstract: Systems, methods, and apparatuses for aggregating merchant offers include a network interface structured to facilitate data communication via a network, an accounts database structured to store account information associated with accounts held by the provider, including a payment account associated with a customer, and a processing circuit comprising a processor and memory. The processing circuit is structured to receive a pre-filtered offer from an offer vendor, aggregate the pre-filtered offer with other received pre-filtered offers from multiple offer vendors to create an aggregated offer list, filter the aggregated offer list based on the account information for the customer to create a filtered offer list, generate a prioritized offer list based on the account information for the customer, and transmit the prioritized offer list to a customer device of the customer.

Abstract: Electrophoretic systems, formulations and methods are described which allow a user to perform electrophoresis experiments under conditions of high voltage and with reduced run time. An electrophoretic system, formulation or method may be run at 50% higher field strength than comparable systems already in use in the art. The presently described systems and formulations may be run at voltages above 225 V, above 250 V, above 275 V, above 300 V, above 325 V or above 350 V. The time required for performing an electrophoresis experiment may be reduced to less than about 30 minutes, less than about 20 minutes, less than about 15 minutes or less than about 12 minutes.

Abstract: An electrophoresis gel with a gel buffer that includes a gel amine buffer, a primary gel ampholyte, and a conjugate gel ampholyte is disclosed herein. The conjugate gel ampholyte may be selected from threonine and serine.

Abstract: An automated peritoneal dialysis (APD) system using gravity to deliver fluid from one or more source dialysate bags to the patient as the destination, and using gravity to deliver fluid from the source patient to the destination drain container or drain receptacle, and heats at least one dialysate bag placed onto a heated plate, and using a disposable tubing set is used for dialysate delivery to and from the patient, and using one or more solenoid-operated, normally closed, electronically-controlled pinch valves which pinch or release the disposable tubing set's tubing to stop or start fluid flow, respectively.

Abstract: An automated peritoneal dialysis (APD) system using gravity to deliver fluid from one or more source dialysate bags to the patient as the destination, and using gravity to deliver fluid from the source patient to the destination drain container or drain receptacle, and heats at least one dialysate bag placed onto a heated plate, and using a disposable tubing set is used for dialysate delivery to and from the patient, and using one or more solenoid-operated, normally closed, electronically-controlled pinch valves which pinch or release the disposable tubing set's tubing to stop or start fluid flow, respectively.

Abstract: Electrophoretic systems, formulations and methods are described which allow a user to perform electrophoresis experiments under conditions of high voltage and with reduced run time. An electrophoretic system, formulation or method may be run at 50% higher field strength than comparable systems already in use in the art. The presently described systems and formulations may be run at voltages above 225 V, above 250 V, above 275 V, above 300 V, above 325 V or above 350 V. The time required for performing an electrophoresis experiment may be reduced to less than about 30 minutes, less than about 20 minutes, less than about 15 minutes or less than about 12 minutes.

Abstract: Provided herein is an apparatus for gel electrophoresis comprising a cassette and a comb having at least one wedge-shaped tooth.

Abstract: A mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprises one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The one or more mutation is preferably within the extracellular leucine-rich repeat domain (LRD) of the TSHR, or within residues 22 to 260 (TSHR260) of the TSHR, or may be in the transmembrane domain (TMD), A mutant TSHR or fragment thereof of the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. A mutant TSHR or fragment thereof according to the invention has a greater thermostability than the equivalent wild type TSHR or fragment as determined by its half-life at a given temperature, and can be purified whilst retaining activity. A mutant TSHR or fragment thereof according to the invention may also be deglycosylated whilst retaining activity.

Abstract: An electrophoresis gel with a gel buffer that includes a gel amine buffer, a primary gel ampholyte, and a conjugate gel ampholyte is disclosed herein. The conjugate gel ampholyte may be selected from threonine and serine.

Abstract: Provided herein is an apparatus for gel electrophoresis comprising a cassette and a comb having at least one wedge-shaped tooth.

Abstract: Electrophoretic systems, formulations and methods are described which allow a user to perform electrophoresis experiments under conditions of high voltage and with reduced run time. An electrophoretic system, formulation or method may be run at 50% higher field strength than comparable systems already in use in the art. The presently described systems and formulations may be run at voltages above 225 V, above 250 V, above 275 V, above 300 V, above 325 V or above 350 V. The time required for performing an electrophoresis experiment may be reduced to less than about 30 minutes, less than about 20 minutes, less than about 15 minutes or less than about 12 minutes.

Abstract: Provided herein is an apparatus for gel electrophoresis comprising a cassette and a comb having at least one wedge-shaped tooth.

Abstract: A splitter unit including a chassis containing splitter cards. The splitter unit includes a central processing unit mounting location. The splitter unit also includes test access devices that are inactive when the central processing unit mounting location is vacant. The splitter unit is configured such that the splitter cards provide passive signal splitting even when the central processing unit mounting location is vacant.